The Edit review

The presentation here is unusually calm for this category. Two molecules, each with a standing monthly figure and its six-month rate printed alongside, and a short description of what each drug actually does — one hormone pathway or two — rather than a claim about how much weight it produces. Nothing is struck through, nothing carries a countdown, and the discount for committing longer is offered as an alternative rather than presented as the real price with the standing rate quietly withheld. That combination is rarer than it ought to be, and its practical effect is that a reader can cost a year on either molecule, at either commitment, straight off the page. What is missing is the dose. Neither figure has a milligram behind it, and both cards mention gradual titration without saying whether the price moves as the titration proceeds. For somebody intending to hold at a low dose, that is precisely the unanswered question — and it is the one thing the page would need to add to be genuinely useful to them rather than merely clear and honest, which it already is.

Vs median

$34/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

The Edit does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

The presentation here is unusually calm for this category. Two molecules, each with a standing monthly figure and the six-month rate printed next to it, and a short description of what each drug actually does — one pathway or two — rather than a claim about how much weight it produces. Nothing is struck through, nothing is labeled limited-time, and the discount for committing is shown as an alternative rather than as the real price with the standing rate hidden. That combination is rarer than it should be, and it means a reader can work out the annual cost of either choice from the page in about ten seconds. What is missing is the dose. Neither figure has a milligram behind it, and both cards mention gradual titration without saying whether the price moves as the titration proceeds. For someone intending to hold at a low dose that is the unanswered question, and it is the one the page would need to answer to be genuinely useful to them rather than merely clear.

No dose is published behind either price.

• Both cards mention titration without saying whether the price changes as the dose rises.
• No compounding pharmacy is named.

The Edit is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What the evidence actually shows
• Microdosing tirzepatide
• The true annual cost of a plan
• Titration planner